NCT06205758

Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,600 (estimated)
• Sponsor: Yi Han · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

1. To evaluate the efficacy and safety of levosimendan and milrinone in the treatment of with acute heart failure with or without renal dysfunction; 2. Predictive modeling of the efficacy and safety of levosimendan and milrinone.

Detailed description

By comparing the safety and efficacy of milrinone with levosimendan as an initial inotropic agent for the treatment of patients with acute heart failure with or without abnormal renal function, a preliminary efficacy and safety prediction model was developed for levosimendan and milrinone based on the basic characteristics of the patients and the level of renal function.

Conditions

• Heart Failure
• Levosimendan
• Milrinone
• Efficacy
• Safety

Timeline

• Start date: 2023-11-16
• Primary completion: 2025-06-01
• Completion: 2025-06-01
• First posted: 2024-01-16
• Last updated: 2024-01-16

Locations

1 site across 1 country: China